Home Health & Hospice Weekly News Roundup

Our weekly list of news, reports, and information about home health and hospice care. Learn about new studies, trends, CMS regulations and more.


LHC Group (LHCG) Earns Overweight Rating from Analysts at Cantor Fitzgerald


Cantor Fitzgerald began coverage on shares of LHC Group (NASDAQ:LHCG) in a report released on Wednesday, September 12th, Marketbeat reports. The firm issued an overweight rating and a $117.00 price target on the health services provider’s stock. Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group raised their target price on LHC Group to $120.00 and gave the stock a buy rating in a research note on Friday, August 3rd. BidaskClub cut LHC Group from a strong-buy rating to a buy rating in a research note on Tuesday, July 10th. Benchmark set a $110.00 target price on LHC Group and gave the stock a buy rating in a research note on Thursday, August 2nd. ValuEngine raised LHC Group from a hold rating to a buy rating in a research note on Saturday, June 2nd. Finally, Zacks Investment Research raised LHC Group from a hold rating to a buy rating and set a $96.00 target price for the company in a research note on Thursday, June 21st.


New Senate Bill Seeks to Loosen Homebound Requirements for Home Health Services


The home health industry has won another victory in Washington, D.C., in its battle against certain parts of the Patient-Driven Groupings Model (PDGM) and shift toward a more pre-acute care identity. Sens. Susan Collins (R-Maine), Bill Nelson (D-Fla.) and Debbie Stabenow (D-Mich.) introduced the Home Health Payment Innovation Act — S. 3545 — on Wednesday. If passed, the bill would amend the Social Security Act and loosen a homebound requirement for Medicare beneficiaries in Medicare Advantage plans.


Amedisys (AMED) Announces Employment Agreement Extension with CEO Paul Kusserow


America’s leading independent home health, hospice and personal care company, announced today that it has extended its employment agreement with Paul Kusserow, its president and CEO, from September 27, 2018 to December 16, 2021, adding three more years. Kusserow joined the Company on December 11, 2014. In the nearly four years since then, he has led Amedisys in a dramatic turnaround clinically, culturally and financially. Under Kusserow’s leadership, Amedisys’ home health star ratings reached an industry-leading average of 4.38 stars; its stock has nearly quintupled, from $26 to an all-time high of $124 and its market cap has almost quadrupled, from $889 million to $3.84 billion.


CMS Revamps the Medicare Program Integrity Manual to Accelerate Innovation, Access to Technology


As part of a broader effort to modernize the Medicare program through IT and innovation, the Centers for Medicare and Medicaid Services today announced changes to the way contractors decide which technologies are covered. CMS has revised its Medicare program integrity manual in updates that follow 21st Century Cures Act requirements for more transparency in the local coverage determination, or LCD, process. In this first revision since August 2015, the manual has been revamped as a roadmap for the LCD process. It lays out CMS's expectations for Medicare Administrative Contractors. MACs determine which healthcare items and services meet requirements for Medicare coverage, taking into account local coverage determinations. LCDs are issued when national determinations do not exist, or when the contractors need to further define a national determination.